Mary M. Rozenman files SEC Form 4 disclosures for Aimmune Therapeutics, Inc.. They have made 2 open-market trades across 1 company since 2017, most recently 2017-12-26.
CIK 0001648920
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AIMT | 129 | $4K |
Shares reported on the most recent Form 4, priced at the 2017-12-28 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.